doi: 10.1046/j.1365-2141.2002.39201.x.
Position paper on imatinib mesylate in chronic myeloid leukaemia
- PMID: 12358935
- DOI: 10.1046/j.1365-2141.2002.39201.x
Item in Clipboard
Position paper on imatinib mesylate in chronic myeloid leukaemia
Br J Haematol.
2002 Oct.
No abstract available
Similar articles
-
Imatinib for chronic myeloid leukaemia: a NICE mess.Lancet. 2001 Nov 3;358(9292):1478. doi: 10.1016/S0140-6736(01)06571-0. Lancet. 2001. PMID: 11705557 No abstract available.
-
The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review.Health Technol Assess. 2002;6(33):1-162. doi: 10.3310/hta6330. Health Technol Assess. 2002. PMID: 12633529 No abstract available.
-
NICE backs leukaemia drug after manufacturer drops price.BMJ. 2012 Mar 22;344:e2274. doi: 10.1136/bmj.e2274. BMJ. 2012. PMID: 22442356 No abstract available.
-
Imatinib for chronic myeloid leukaemia: a NICE mess.Lancet. 2001 Dec 1;358(9296):1902-3. doi: 10.1016/s0140-6736(01)06902-1. Lancet. 2001. PMID: 11741654 No abstract available.
-
Imatinib mesylate--a new oral targeted therapy.N Engl J Med. 2002 Feb 28;346(9):683-93. doi: 10.1056/NEJMra013339. N Engl J Med. 2002. PMID: 11870247 Review. No abstract available.
Cited by
-
The use of isobaric tag peptide labeling (iTRAQ) and mass spectrometry to examine rare, primitive hematopoietic cells from patients with chronic myeloid leukemia.Mol Biotechnol. 2007 Jun;36(2):81-9. doi: 10.1007/s12033-007-0005-5. Mol Biotechnol. 2007. PMID: 17914187
-
Emerging Insights into Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Induced by Immune Checkpoint Inhibitor and Tumor-Targeted Therapy.J Inflamm Res. 2024 Apr 17;17:2337-2351. doi: 10.2147/JIR.S454673. eCollection 2024. J Inflamm Res. 2024. PMID: 38645875 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
